Blood filtering may tame severe immunotherapy side effects

NCT ID NCT07756242

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study looks at whether a procedure called therapeutic plasma exchange—which filters the blood—can help remove immune checkpoint inhibitor drugs from the body in people who develop severe immune-related side effects from cancer treatment. The trial will measure how drug levels change during and after the procedure in about 15 adults with cancer who are receiving or recently received these immunotherapy drugs. The goal is to understand how plasma exchange affects drug levels, which could guide future management of these serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Therapeutic plasma exchange using the Spectra Optia Apheresis System
What this could lead to
If successful, this could help doctors better manage severe immune-related side effects from cancer immunotherapy by understanding how plasma exchange clears these drugs from the body.
What could go wrong
This is a small early-phase study with only 15 participants, so results may not apply broadly. Plasma exchange carries risks like bleeding, infection, or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE-RELATED ADVERSE EVENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Chicago

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.